Cargando…

Clinical and Biological Implications of MYC Activation: A common difference between MGUS and newly diagnosed multiple myeloma

Events mediating transformation from the pre-malignant monoclonal gammopathy of undetermined significance (MGUS) to multiple myeloma (MM) are unknown. We analyzed a gene expression datasets generated on the Affymetrix U133 platform from 22 MGUS and 101 MM patients using gene-set enrichment analysis....

Descripción completa

Detalles Bibliográficos
Autores principales:	Chng, WJ, Huang, GF, Chung, TH, Ng, SB, Gonzalez-Paz, N, Troska-Price, T, Mulligan, G, Chesi, M, Bergsagel, PL, Fonseca, R
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432644/ https://www.ncbi.nlm.nih.gov/pubmed/21468039 http://dx.doi.org/10.1038/leu.2011.53

Ejemplares similares

MYC dysregulation in the progression of multiple myeloma
por: Misund, K, et al.
Publicado: (2019)

Promiscuous Rearrangements of the MYC Locus Hijack Enhancers and Super-Enhancers to Dysregulate MYC Expression in Multiple Myeloma
por: Affer, Maurizio, et al.
Publicado: (2014)

Plasmacytoid Dendritic Cells in Patients with MGUS and Multiple Myeloma
por: Knight, Andrea, et al.
Publicado: (2021)

Active multiple myeloma suppresses and typically eliminates coexisting MGUS
por: Campbell, John P, et al.
Publicado: (2017)

MGUS bone
por: Imataki, Osamu, et al.
Publicado: (2019)

Analysis of the Targets and Glycosylation of Monoclonal IgAs From MGUS and Myeloma Patients
por: Bosseboeuf, Adrien, et al.
Publicado: (2020)

Serum BCMA levels predict outcomes in MGUS and smoldering myeloma patients
por: Visram, A., et al.
Publicado: (2021)

Multiple myeloma in a kidney transplanted patient primarily diagnosed with monoclonal gammopathy of unknown significance (MGUS)-related nephropathy
por: Resuli, Marsela, et al.
Publicado: (2013)

A gene signature can predict risk of MGUS progressing to multiple myeloma
por: Sun, Fumou, et al.
Publicado: (2023)

PB2073: EVALUATION OF THE PLASMA METABOLOMIC PROFILE OF MGUS AND MULTIPLE MYELOMA PATIENTS
por: Ciesluk, Klaudia, et al.
Publicado: (2023)

Inheritance in MGUS and MM
por: Pfreundschuh, Michael
Publicado: (2015)

Angiogenic cytokines profile in smoldering multiple myeloma: No difference compared to MGUS but altered compared to symptomatic myeloma
por: Gkotzamanidou, Maria, et al.
Publicado: (2013)

A simple additive staging system for newly diagnosed multiple myeloma
por: Abdallah, Nadine H., et al.
Publicado: (2022)

Changes in uninvolved immunoglobulins during induction therapy for newly diagnosed multiple myeloma
por: Ravi, P, et al.
Publicado: (2017)

Alterations in bone marrow metabolism are an early and consistent feature during the development of MGUS and multiple myeloma
por: Ludwig, C, et al.
Publicado: (2015)

Role of erythropoietin in the angiogenic activity of bone marrow endothelial cells of MGUS and multiple myeloma patients
por: Lamanuzzi, Aurelia, et al.
Publicado: (2016)

Subclonal evolution in disease progression from MGUS/SMM to multiple myeloma is characterised by clonal stability
por: Dutta, Ankit K., et al.
Publicado: (2018)

Ulcerating necrobiotic xanthogranuloma: A clinical sign to reconsider progression from MGUS to multiple myeloma
por: Fay, Christopher J., et al.
Publicado: (2023)

Two Cases of Heavy Chain MGUS
por: Van Keer, Jan, et al.
Publicado: (2016)

Severe CIDP-MGUS responsive to Rituximab
por: Posa, Andreas, et al.
Publicado: (2020)

Myeloma precursor disease (MGUS) among rescue and recovery workers exposed to the World Trade Center disaster
por: Zeig-Owens, Rachel, et al.
Publicado: (2022)

PB2072: CIRCULATING CD71+ MYELOID PRECURSORS IN MGUS AND MULTIPLE MYELOMA: A PROSPECTIVE SURVEY
por: Parrinello, Nunziatina Laura, et al.
Publicado: (2023)

Oprozomib in patients with newly diagnosed multiple myeloma
por: Hari, Parameswaran, et al.
Publicado: (2019)

Daratumumab in untreated newly diagnosed multiple myeloma
por: Abdallah, Nadine, et al.
Publicado: (2019)

Acquired platelet dysfunction in newly diagnosed myeloma
por: Mortimer, Joshua, et al.
Publicado: (2021)

A Focus on Newly Diagnosed Multiple Myeloma
por: Brigle, Kevin, et al.
Publicado: (2022)

UCHL1 is a biomarker of aggressive multiple myeloma required for disease progression
por: Hussain, Sajjad, et al.
Publicado: (2015)

Serum protein fingerprinting by PEA immunoassay coupled with a pattern-recognition algorithms distinguishes MGUS and multiple myeloma
por: Schneiderova, Petra, et al.
Publicado: (2016)

Predicting long-term disease control in transplant-ineligible patients with multiple myeloma: impact of an MGUS-like signature
por: Rodríguez-Otero, Paula, et al.
Publicado: (2019)

Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1
por: Bosseboeuf, Adrien, et al.
Publicado: (2020)

Phase I/II study of melphalan, prednisone and lenalidomide combination for patients with newly diagnosed multiple myeloma who are not candidates for stem cell transplantation
por: Roy, V, et al.
Publicado: (2015)

Review of thalidomide in the treatment of newly diagnosed multiple myeloma
por: Cavallo, Federica, et al.
Publicado: (2007)

Laboratory Features of Newly Diagnosed Multiple Myeloma Patients
por: Hussain, Azhar, et al.
Publicado: (2019)

Frontline therapy for newly diagnosed patients with multiple myeloma
por: Jung, Sung-Hoon, et al.
Publicado: (2020)

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma
por: Libby, Edward, et al.
Publicado: (2020)

A Novel Measure of Chromosome Instability Can Account for Prognostic Difference in Multiple Myeloma
por: Chung, Tae-Hoon, et al.
Publicado: (2013)

Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma
por: Matthews, G M, et al.
Publicado: (2013)

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma
por: Dimopoulos, Meletios A., et al.
Publicado: (2020)

Monoclonal gammopathy of renal significance (MGRS) increases the risk for progression to multiple myeloma: an observational study of 2935 MGUS patients
por: Steiner, Normann, et al.
Publicado: (2017)

Mass Cytometry Discovers Two Discrete Subsets of CD39(−)Treg Which Discriminate MGUS From Multiple Myeloma
por: Marsh-Wakefield, Felix, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_j0q01grv299l8k3v46ut6qmrhm